331 related articles for article (PubMed ID: 30442523)
1. Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.
Myall NJ; Henry S; Wood D; Neal JW; Han SS; Padda SK; Wakelee HA
Clin Lung Cancer; 2019 Mar; 20(2):e208-e217. PubMed ID: 30442523
[TBL] [Abstract][Full Text] [Related]
2. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
Cardarella S; Ogino A; Nishino M; Butaney M; Shen J; Lydon C; Yeap BY; Sholl LM; Johnson BE; Jänne PA
Clin Cancer Res; 2013 Aug; 19(16):4532-40. PubMed ID: 23833300
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
5. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
Wiesweg M; Preuß C; Roeper J; Metzenmacher M; Eberhardt W; Stropiep U; Wedeken K; Reis H; Herold T; Darwiche K; Aigner C; Stuschke M; Schildhaus HU; Schmid KW; Falk M; Heukamp L; Tiemann M; Griesinger F; Schuler M
Eur J Cancer; 2021 May; 149():211-221. PubMed ID: 33872981
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
Horn L; Bauml J; Forde PM; Davis KL; Myall NJ; Sasane M; Dalal A; Culver K; Wozniak AJ; Baik CS; Mutebi A; Zhang P; Wakelee HA; Johnson BE
Lung Cancer; 2019 Feb; 128():74-90. PubMed ID: 30642457
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
Couraud S; Barlesi F; Fontaine-Deraluelle C; Debieuvre D; Merlio JP; Moreau L; Beau-Faller M; Veillon R; Mosser J; Al Freijat F; Bringuier PP; Léna H; Ouafik L; Westeel V; Morel A; Audigier-Valette C; Missy P; Langlais A; Morin F; Souquet PJ; Planchard D;
Eur J Cancer; 2019 Jul; 116():86-97. PubMed ID: 31181537
[TBL] [Abstract][Full Text] [Related]
8. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.
Marchetti A; Felicioni L; Malatesta S; Grazia Sciarrotta M; Guetti L; Chella A; Viola P; Pullara C; Mucilli F; Buttitta F
J Clin Oncol; 2011 Sep; 29(26):3574-9. PubMed ID: 21825258
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
Dudnik E; Bar J; Peled N; Bshara E; Kuznetsov T; Cohen AY; Shochat T; Nechushtan H; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadar N; Urban D; Mishaeli M; Rabinovich NM; Brenner R; Zer A; Rotem O; Roisman LC; Wollner M;
Clin Lung Cancer; 2019 Jul; 20(4):278-286.e1. PubMed ID: 31060855
[TBL] [Abstract][Full Text] [Related]
10. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics.
Salimian KJ; Fazeli R; Zheng G; Ettinger D; Maleki Z
Acta Cytol; 2018; 62(2):79-84. PubMed ID: 29320776
[TBL] [Abstract][Full Text] [Related]
11. Patients with non-small-cell lung cancer harbouring a
Auliac JB; Bayle S; Vergnenegre A; Le Caer H; Falchero L; Gervais R; Doubre H; Vinas F; Marin B; Chouaid C
Curr Oncol; 2018 Oct; 25(5):e398-e402. PubMed ID: 30464690
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation.
Ding X; Zhang Z; Jiang T; Li X; Zhao C; Su B; Zhou C
Cancer Med; 2017 Mar; 6(3):555-562. PubMed ID: 28135039
[TBL] [Abstract][Full Text] [Related]
13. Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
Sakai T; Matsumoto S; Ueda Y; Shibata Y; Ikeda T; Nakamura A; Kodani M; Ohashi K; Furuya N; Izumi H; Nosaki K; Umemura S; Zenke Y; Udagawa H; Sugiyama E; Yoh K; Goto K
J Thorac Oncol; 2023 Nov; 18(11):1538-1549. PubMed ID: 37543207
[TBL] [Abstract][Full Text] [Related]
14. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort.
Lim GHT; Balbi KJ; Poskitt B; Bennett P; Moore DA
Lung Cancer; 2022 Nov; 173():71-74. PubMed ID: 36156323
[TBL] [Abstract][Full Text] [Related]
17. A large-scale, multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer.
Wu H; Feng J; Lu S; Huang J
Cancer Med; 2024 May; 13(10):e7305. PubMed ID: 38770647
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer.
Goldman JM; Gray JE
Cancer Genet; 2015 Jun; 208(6):351-4. PubMed ID: 26066373
[TBL] [Abstract][Full Text] [Related]
20. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
